Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Parallel-Group, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and Compared With Vedolizumab in Patients With Moderate to Severe Ulcerative Colitis

Trial Profile

A Phase II, Randomized, Parallel-Group, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and Compared With Vedolizumab in Patients With Moderate to Severe Ulcerative Colitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2019

At a glance

  • Drugs RG 7880 (Primary) ; Vedolizumab
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 01 Feb 2019 Planned End Date changed from 13 May 2021 to 24 Sep 2021.
    • 01 Feb 2019 Planned primary completion date changed from 15 Dec 2020 to 23 Apr 2021.
    • 17 Aug 2018 Planned number of patients changed from 330 to 270.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top